Aptevo Therapeutics Inc.

12/12/2024 | Press release | Distributed by Public on 12/12/2024 08:22

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.